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Yeast infections after 
esophagectomy: A Retrospective 
Analysis
Marjolein Heuker1,6, Usma Koser2,6, Alewijn ott3, Arend Karrenbeld4, Jan Maarten van Dijl  1, 
Gooitzen M. van Dam2,5, Anne Marie G. A. de Smet2 & Marleen van oosten1*
Esophageal malignancy is a disease with poor prognosis. Curative therapy incorporates surgery and 
is burdensome with high rates of infection morbidity and mortality. The role of yeast as causative 
organisms of post-esophagectomy infections is poorly defined. Consequently, the benefits of specific 
antifungal prophylactic therapy in improving patient outcome are unclear. Therefore, this study aimed 
at investigating the incidence of yeast infections at the University Medical Center Groningen among 
565 post-esophagectomy patients between 1991 and 2017. The results show that 7.3% of the patients 
developed a yeast infection after esophageal resection with significantly increased incidence among 
patients suffering from diabetes mellitus. For patients with yeast infections, higher Acute Physiology 
and Chronic Health Evaluation (APACHE) II scores, more frequent intensive care unit readmissions, 
prolonged hospital stays and higher mortality rates were observed. One-year survival was significantly 
lower for patients with a yeast infection, as well as diabetes mellitus and yeast-positive pleural effusion. 
We conclude that the incidence of yeast infections following esophagectomy is considerable, and that 
patients with diabetes mellitus are at increased risk. Furthermore, yeast infections are associated 
with higher complication rates and mortality. These observations encourage further prospective 
investigations on the possible benefits of antifungal prophylactic therapy for esophagectomy patients.
Esophageal cancer is an aggressive disease associated with poor prognosis and a 5-year survival of 10%1,2. The 
curative treatment, when applicable, is neo-adjuvant chemoradiotherapy with surgical resection and radical lym-
phadenectomy. Although some benign disorders can result in esophagectomy, esophageal malignancy is the main 
reason for resection. Despite medical, surgical, nutritional and critical care advances, esophagectomy remains 
an operative intervention with high morbidity and mortality even when compared to other complex surgical 
procedures. Mortality rates vary depending on many factors and have been reported as 5–10%3–5. However, 
morbidity occurs in over 50% of cases and pulmonary complications, are almost universally seen as the great-
est post-operative challenge for healthcare providers6. Moreover, patients who suffer from pneumonia show a 
seven-fold increase in mortality7. Causative microorganisms for pulmonary infection usually belong to the oro-
pharyngeal flora, as this is likely the result of cervical anastomosis leakage.
Risk factors for yeast infections can be split into host, pathogen and health-care associated aspects. In the 
former category, immune-compromising conditions, older age, malignancy, corticosteroid or cytotoxic therapy 
and neutropenia have all shown to increase the risk of invasive Candida infections8. Mechanically ventilated, crit-
ically ill patients suffer from colonization with Candida species in 25% of cases, whereas colonization occurs in 
50% of the patients suspected of ventilator-associated pneumonia9. Nevertheless, pneumonia caused by Candida 
is rare10. On the other hand, systemic yeast infections are associated with increased morbidity and mortality9,11. 
Complex diagnostics and clinical uncertainty in these, often critically ill patients, can lead to at least a challenging 
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management course and at worst futile demise. Therefore, a prophylactic treatment strategy for high-risk patients 
may be of benefit and result in improved clinical progress and overall patient outcomes11.
Several studies have suggested selective decontamination of the digestive tract (SDD) and selective oropharyn-
geal decontamination (SOD) can reduce the (pulmonary) infection rates and improve survival in surgical and 
non-surgical intensive care unit (ICU) patients12–15. The selective decontamination principle is based on eradica-
tion of certain pathogens (i.e. aerobic Gram-negative bacteria, Staphylococcus aureus and yeast), resulting in fewer 
ICU-acquired infections. In 2011, a double-blind randomized controlled trial was carried out to evaluate the 
effect of SDD (a regimen consisting of oral, non-absorbable paste and enteral antibiotics including amphotericin 
B, tobramycin, colistin and intravenous cefotaxime or other third generation cephalosporins) or placebo in addi-
tion to standard antibiotic prophylaxis in patients receiving elective gastrointestinal surgery16. SDD in addition to 
the standard intravenous antibiotics reduced the incidence of postoperative infections and anastomotic leakage.
Given the serious implications of systemic yeast infections, the effects of SDD should be investigated in more 
depth in esophagectomy patients to identify whether this patient group may also benefit from tailored SDD15–17. 
However, thus far it is not known to what extent esophagectomy patients develop yeast infections and whether 
addition of an antifungal to a topical antibacterial application of polymyxin B and tobramycin pre-operatively 
may be useful as an infection prevention measure. Therefore, in this study, we retrospectively analyzed yeast 
infections, clinical and demographic data and complications in patients following esophageal resection at the 
University Medical Center Groningen (UMCG).
Results
Patient characteristics and outcomes. The investigated patient cohort consisted of 565 patients 
who underwent esophageal resection in the UMCG between January 1991 and July 2017 (Fig. 1). More males 
underwent esophagectomy (sex ratio M:F, 4:1) and the mean age of this study population was 63.8 ± 9.1 years 
(mean ± SD). Resection was performed via minimal invasive esophagectomy (MIE) in 8.3% (n = 47), via an open 
procedure in 90.1% (n = 509), and by colon interposition (n = 9) in 1.6% of the cases (Table 1). 7.3% (n = 41) of 
the patients developed a yeast infection after surgery. In one patient the diagnosis of yeast infection was made 
at autopsy, and this was in accordance with the clinical features. Patients with diabetes mellitus (DM) developed 
a yeast infection significantly more often than patients without (odds ratio (OR) 3.4; 95% confidence interval 
(CI): 1.6–7.0; p = 0.001; Table 1). A higher APACHE II score (p = 0.028), readmission to the ICU (OR 6.7; 95% 
CI: 3.5–13.0; p < 0.001) and longer hospitalization (p < 0.001) were all associated with yeast infection (Table 1). 
Other comorbidities and characteristics of the group with yeast infection and the group with no yeast infection 
are displayed in Table 1.
An overview of antifungal treatment is presented in Supplementary Fig. S1. Antifungal treatment did not 
have a significant effect on mortality (30 day mortality p = 0.305; 3 month mortality p = 0.246; 1 year mortality 
p = 0.174). Additional surgical intervention was documented for 43.9% (n = 18) of the patients with yeast infec-
tions. Almost all patients with a yeast infection did have a drain (n = 39). 30 day mortality was independent of 
surgery in patients with a drain (p = 1.000). However, these numbers are too small to draw any further conclu-
sions. For a more extensive overview of mortality data, we refer to Supplementary Table S1, where the mortality in 
the yeast and no yeast infection groups is shown as recorded before 2006, between 2006 and 2014, and after 2014. 
These specific time periods were chosen because of the introduction of neoadjuvant chemoradiotherapy in 2006 
and MIE in 2015. Supplementary Table S2 shows an overview of the pTNM (Tumor Node Metastases; pathology) 
and ypTNM (pathology after neoadjuvant chemoradiotherapy) classification. We found no relation to more yeast 
infections with increasing severity of pathological disease.
Characteristics of yeast infections and drain cultures. A yeast infection was identified in 41 patients 






- incomplete datasets (n=49)
- unknown comorbidities (n=2)
Yeast infection 
(n=41)
Figure 1. Flowchart of the study design.
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Variable Yeast infection No yeast infection P value
Demographic characteristics n = 41 n = 524
Age during surgery 64.8 ( ± 8.9) 63.8 ( ± 9.1) 0.497
Gender 0.155
  Male 36 (87.8%) 411 (78.3%)
  Female 5 (12.2%) 113 (21.7%)
Comorbidities n = 41 n = 524
HIV infection 0 (0.0%) 0 (0.0%)
Chronic renal insufficiency 0 (0.0%) 7 (1.3%) 1.000
Chronic respiratory insufficiency 0 (0.0%) 2 (0.4%) 1.000
Cirrhosis 1 (2.4%) 6 (1.1%) 0.412
COPD 7 (17.1%) 53 (10.1%) 0.184
CVA 3 (7.3%) 18 (3.4%) 0.190
CVD 1 (2.4%) 38 (7.3%) 0.501
DM 12 (29.3%) 57 (10.9%) 0.001*
Immunological insufficiency 9 (22.0%) 134 (25.6%) 0.608
Diagnosis n = 41 n = 524
Esophageal cancer 38 (92.7%) 506 (96.6%) 0.190
Other malignancy 2 (4.9%) 16 (3.05%) 0.381
No malignancy 1 (2.4%) 2 (0.4%) 0.203
Type of esophageal carcinoma n = 38 n = 506
Adenocarcinoma 30 (79.0%) 411 (81.2%) 0.711
Squamous cell carcinoma 8 (21.1%) 82 (16.2%) 0.438
Other carcinoma 0 (0.0%) 3 (0.6%) 1.000
Dysplasia 0 (0.0%) 10 (2.0%) 1.000
Patients with no esophageal cancer were excluded (n = 21, with yeast infection n = 3 and with no yeast 
infection n = 18).
Type of surgery n = 41 n = 524
Open esophagectomy 39 (95.1%) 470 (89.7%) 0.413
MIE 1 (2.4%) 46 (8.8%) 0.238
Colon interposition 1 (2.4%) 8 (1.5%) 0.495
Mortality n = 41 n = 522
30D 5 (12.2%) 21 (4.0%) 0.039*
3 M 9 (22.0%) 33 (6.3%) 0.002*
1Y 21 (51.2%) 118 (22.6%) <0.001*
Patients with unknown date of death were excluded (n = 2).
Yeast colonization n = 30 n = 281
16 (53.3%) 106 (37.7%) 0.096
Patients without cultures were excluded (n = 254).
APACHE scores n = 24 n = 258
II 13.5 ( ± 4.1) 12.6 (±3.7) 0.028*
IV n = 26 n = 269
50.4 ( ± 17.8) 42.2 (±13.9) 0.348
Patients with unknown APACHE II (n = 281) and APACHE IV (n = 270) scores were excluded.
Readmission to ICU n = 41 n = 524
22 (53.7%) 77 (14.7%) <0.001*
Length of hospital stay n = 25 n = 255
54.2 ( ± 33.3) 20.3 ( ± 12.7) <0.001*
Patients with unknown length of hospital stay were excluded (n = 285).
Table 1. Patient characteristics. Values represent mean (SD; standard deviation) or numbers (%). AIDS, acquired 
immune deficiency syndrome; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; 
CVD, cardiovascular disease (myocardial infarction before intensive-care admission and chronic cardiovascular 
insufficiency); DM, diabetes mellitus; MIE, minimal invasive esophagectomy; 30D, 30 day mortality; 3 M, 
3 month mortality; 1Y, 1 year mortality; APACHE, Acute Physiology and Chronic Health Evaluation; ICU, 
intensive-care unit. Immunological insufficiencies included long term immunosuppressive therapy; corticosteroid 
use (both short term high and long term low dosages, e.g. > 5 days 1 mg/kg prednisolone or more than 20 
days > 0.1 mg/kg); active chemo- or radiotherapy in the past year; chemo- or radiotherapy for Hodgkin’s or non-
Hodgkin’s lymphoma at any time prior to ICU admission; humoral or cellular deficiencies. No malignancies 
include achalasia, extra lobar pulmonary sequestration and the Boerhaave syndrome. Open esophagectomy 
included n = 2 patients with a partial resection of the esophagus due to a leiomyoma. *P values < 0.05 were 
considered significant.
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Anastomotic leakage was observed to be the main cause of yeast infection (n = 32; Fig. 2A). Only 2 patients 
developed candidemia from an unknown source (Fig. 2A). Candida albicans was the causative species in the 
majority of these cases (Fig. 2B). Drain fluid was cultured from 96 patients, mainly because of suspected anasto-
motic leakage. An overview of the drain cultures in comparison with mortality, survival and readmission to the 
ICU is presented in Table 2 and Fig. 2C. Table 2 details numbers of cultures with or without yeast growth but not 
necessarily a treated yeast infection.
Survival analysis. The survival of patients with a diagnosed yeast infection was lower compared to patients 
without a yeast infection (p < 0.001; Fig. 3A), and patients with DM presented a statistically significant increase 
in overall yeast infection (Table 1). Therefore, a survival analysis was performed to evaluate this patient group 
(Fig. 3B). Indeed, a higher one-year mortality for DM patients with a yeast infection compared to patients with-
out yeast infection (p = 0.003) was demonstrated. To analyze whether a positive yeast culture in drain fluid from 
patients with a suspected cervical anastomosis leakage is reflected in the respective patients’ survival, we com-
pared the outcomes of patients with positive or negative yeast culture from polymicrobial drain fluids. Figure 3C 
shows a substantial reduction in survival of patients whose drain fluid contained a polymicrobial contamination 
that tested positive upon yeast culture (p = 0.005). Although not all patients with yeast-positive drain cultures 
were defined as having a yeast infection, the presence of yeast in drain fluid is indicative for an effect on survival.
A B
C Drain cultures (n = 96)

















Figure 2. Possible causes and identification of yeast infections. The underlying cause of a yeast infection (A), 
causative species (B) and pleural drain cultures with and without yeast (C) are shown. In figure C, 3 patients 
with a yeast infection had a negative pleural drain culture but a positive culture from an alternate site and 3 
patients who were defined as infection did not have a pleural drain culture sent for analysis and diagnosis was 
again made from an alternate site. *Candidemia was only detected in 2 patients. The source of both candidemia 





- yeast P value
Mortality n = 50 n = 46
30D 5 (10.0%) 2 (4.3%) 0.438
3 M 10 (20.0%) 3 (6.5%) 0.054
1Y 24 (48.0%) 10 (21.7%) 0.070
Survival > 1Y 26 (52.0%) 36 (78.3%) 0.070
Readmission to 
ICU 0.039*
yes 29 (58.0%) 29 (63.0%)
no 21 (42.0%) 17 (37.0%)
Table 2. Microbiological analysis of drain cultures. Values represent numbers (%). 30D, 30 day mortality; 3 M, 
3 month mortality; 1Y, 1 year mortality; survival > 1Y, > 1 year survival. Drain cultures with 2 different yeast 
species without bacterial growth (n = 2) and one yeast species without bacterial growth (n = 6) were included in 
the (poly)microbial + yeast group. Drain cultures containing one bacterial species (n = 25) were included in the 
(poly)microbial - yeast group. *P values < 0.05 were considered significant.
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Discussion
In this study, we determined the incidence of yeast infections in esophageal resection patients between 1991 
and 2017 at the UMCG. 7.3% of patients who underwent esophagectomy developed a yeast infection, the most 
prevalent organism being C. albicans. The most frequent underlying cause was identified as anastomotic leakage. 
Patients with DM had a statistically significant risk over other detailed comorbidities for developing a yeast infec-
tion. Furthermore, there was a significant increase in mortality rates between those in the defined yeast infection 
versus the non-yeast infection group.
Culture of drain fluid (n = 96)
Paents with diabetes mellitus (n = 69)
Paents aer oesophageal resecon (n = 565)A
B
C
Figure 3. Survival analysis of patients with or without yeast infection. Survival curves of (A) patients with yeast 
infection vs. non-yeast infection, (B) yeast infection vs. non-yeast infection in patients with diabetes mellitus, 
(C) patients with (poly)microbial drain culture + yeast vs. (poly)microbial drain cultures - yeast.
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Invasive yeast infections pose a clinical challenge as they have a significant impact on patient outcome, result-
ing in up to 50% increased mortality18,19. Recent studies have shown point prevalence rates of candidemia at 
6.9 per 1000 ICU patients with 7.5% of patients requiring systemic antifungal therapy20. These figures are from 
general ICU populations and although comparisons are made with caution, we note similarity to the antifungal 
therapy required to treat patients included in our study (7.3%). However, the observed candidemia rate was lower 
compared to the literature (4.9%; n = 2).
Previous studies have shown a correlation between invasive fungal infections and high APACHE II scores21,22. 
However, others have failed to corroborate this link23. In our present study, higher APACHE II scores were signif-
icantly (p = 0.028) correlated to the development of yeast infection.
Notably, DM was identified as the only chronic disease that showed a statistically significant association to 
the development of yeast infections. There has long been a multifactorial correlation between DM and both 
general and surgery-specific infections24,25. DM is also a preoperative predictor of mortality in esophagectomy 
patients with increased morbidity and mortality5,26. A systematic review by Li and colleagues demonstrated a 
link between anastomotic leakage and DM in esophagectomy patients following a similar conclusion in general 
abdominal surgery patients27,28. We identified anastomotic leakage as the most prevalent underlying etiology 
of complications (Fig. 2), which is consistent with the results of Raymond et al. who illustrated 12.0% anas-
tomotic leakage and 12.2% pneumonia in 4321 esophagectomy patients2. However, the results of our current 
study provide no evidence for the same incidence of documented pneumonia. Given the link between cervical 
anastomotic leakage and pulmonary and polymicrobial infections, the relationship between DM and the devel-
opment of yeast infection is likely based on a multifaceted interaction. Polymicrobial positive culture from pleural 
effusion can be logically explained, in this patient category, by cervical anastomotic leakage. Accordingly, the 
presence of gastro-intestinal microbial flora on pleural fluid culture is usually part of the diagnostic tree. Further, 
it should be noted that diagnosis of anastomotic leakage is often difficult as current radiological investigations 
are non-specific. It is therefore conceivable that the prevalence of yeast infection can be attributed to an increased 
incidence of anastomotic leakage in DM patients.
Patients with a yeast infection showed a 2.5-fold increase in mean length of hospital stay compared to the 
overall group, which can be explained by the increased therapy and critical care support these patients are known 
to require. According to the data collected between 2006 and 2014, 8.4% of patients were diagnosed with yeast 
infections. This is in contrast with data collected after 2014 when only 4.5% of patients developed a yeast infec-
tion. We assume that after the introduction of MIE, less yeast infections developed post-esophagectomy. However, 
the numbers are small and to draw firmer conclusions larger sample sizes would be needed.
There are a few limitations to this study. Firstly, the distinction of yeast infection from colonization is chal-
lenging and, accordingly, there is no universally adopted definition11,29. Therefore, we have reduced potential 
diagnostic ambiguity by incorporating current clinical practice and guidelines30. It is important to emphasize 
that the colonized patients were those who had shown a positive yeast culture on routine sampling. However, 
one should bear in mind that yeast is a component of the human mucosal microbiota despite not always being 
cultured. It is also necessary to mention the sporadic use of SDD in some patients in our study, which involved the 
administration of an oral, non-absorbable paste with enteral antibiotics including amphotericin B, tobramycin 
and colistin, as well as intravenous administration of cefotaxime. This was not a global policy adopted by all of the 
ICUs within the UMCG and, therefore, the numbers are believed to be small. From October 2005 to April 2006 
the SDD-regimen was infrequently used as part of a clinical trial12. Additionally, from the summer of 2013, some 
of this patient cohort may have received SDD. This was introduced as a general infection prevention measure 
in the ICU following the aforementioned trial, but not used in all esophagectomy patients. Unfortunately, exact 
numbers are not known since this information relies on subjective documentation by the medical team.
We appreciate the applied definition of yeast infection may lead to potential bias. Our clinical opinion is that 
patients who commenced therapy were more acutely unwell, which complicates interpretation of our retrospective 
survival analysis. However, we additionally evaluated the drain fluid with (poly)microbial contamination, presum-
ably derived from patients with anastomotic leakage. These patients are not routinely subject to antifungal therapy. 
Patients with yeast in their pleural drain fluid showed a diminished survival and therefore, it seems that even the 
presence of yeast is indicative for survival outcome. However, we recognize this could be the result of increased 
antimicrobial administration in critically ill patients, resulting in yeast overgrowth. Further, yeast colonization 
was detected by sputum or throat cultures in the pre- or early post-operative period. From the numbers shown in 
Table 1, no significant effect of colonization on yeast infection can be inferred. However, the diagnostic microbi-
ology laboratory did not consistently report all yeast in sputum cultures during this period and patients were not 
routinely screened for yeast colonization. Consequently, not all cases of yeast-colonization will have been detected.
Other limitations to this study are mainly related to the retrospective nature of the work and thus, inherent 
susceptibility to confounding and bias. Our statistical analysis was designed to take these factors into consider-
ation. Given the electronic patient notes are reliant on user input, we were unable to have complete datasets for 
all patients. In particular, we were unable to obtain information on pre-operative functional assessment, SDD 
prophylaxis, smoking status, definitive steroid or H2 histamine receptor blocker administration, total parenteral 
nutrition and alcohol intake for all the subjects. Moreover, the use of antimicrobial therapy in addition to SDD 
was sourced from ICU discharge letters, overall admission discharge letters and the reports from the consulted 
clinical microbiologist. As the clinical microbiologist was contacted for all patients with yeast infections, the anti-
microbial therapy is believed to be accurate for this group.
Lastly, SDD therapy is mainly applied in the Netherlands, because it is supported by several prospective, 
multi-center randomized controlled trials10,12. However, there has been no prospective investigation on whether 
antifungal prophylaxis, especially pre-operatively, should be used in esophagectomy patients. Although the pres-
ent results should be interpreted with caution, our findings encourage further prospective investigations on the 
possible benefits of antifungal cover in the SDD regimen of esophagectomy patients.
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Methods
Study design and population. At the UMCG we carried out a retrospective analysis of all esophagec-
tomy patients between January 1991 and July 2017. In total, there were 616 surgical procedures. We analyzed 
565 patients. Patients with incomplete data sets (i.e. laboratory outcomes (n = 49)) and unknown comorbidities 
(n = 2) were excluded (Fig. 1). We distinguished patients who developed a yeast infection after surgery and those 
who did not. During the study period, patients admitted to the UMCG complied with hospital guidelines in an 
opt-out research consent procedure. Consequently, individual written consent was not required for the inclusion 
of these patients to our retrospective study. Unless stated otherwise in the medical file, consent was given through 
this opt-out practice. Permission for this study, including the opt-out patient consent protocol, was obtained from 
the Medical Ethical Review Board Committee (Medisch Ethische Toetsingscommissie METc) UMCG, and all 
collected data was treated pseudo-anonymously and in adherence with the Declaration of Helsinki.
Definitions. Yeast colonization was defined as a positive sputum and/or throat culture, or yeast detected in a 
Gram staining of sputum 1 day preoperative until 3 days postoperative. A yeast infection was defined as a positive 
yeast culture in primarily sterile materials (including pus, drain, pleural and wound fluid) with subsequent treat-
ment of the patient with antifungal therapy during hospitalization. Additionally, a yeast positive blood culture or 
a positive culture of a sterile site after autopsy was regarded as a yeast infection.
Data collection. Data was obtained via the electronic health record systems of the UMCG (PoliPlus until 
November 2017 and Electronic Patient Dossier (EPD) from December 2017 onward) and the laboratory infor-
mation systems of the Department of Medical Microbiology (General Laboratory Information Management 
System; GLIMS and ‘Bacteriologisch Ziekenhuisinformatiesysteem’; BACZIS). Several demographic character-
istics, microbiological results and patient comorbidities were identified. Moreover, surgery-specific informa-
tion, pathological diagnosis and ICU admission criteria and subsequent mortality figures were also collected. 
The National Intensive Care Evaluation database (NICE) and the national pathology database (PALGA; 
‘Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief ’) were additional information sources consulted.
Statistical analysis. Unpaired t-tests, Mann-Whitney U tests and Chi square were performed using IBM 
SPSS Statistics 23. The Fisher’s exact test was used when >20% cells had an expected count less than 5. P-values 
of 0.05 or less were considered significant. Aforementioned tests were used to compare the data of the two groups 
(yeast infection vs. no yeast infection and (poly)microbial + yeast vs. (poly)microbial - yeast). To test for trend we 
used the Mantel-Haenszel test. Specifically, to assess a possible higher yeast infection risk with increasing severity 
of pathological disease, a binary logistic regression analysis was performed with three TNM (pathology) classes, 
Tis-I, II and III-IV as a linear variable in the equation and yeast infection as outcome variable. One-year survival 
differences were tested for significance with Cox regression analysis.
Received: 22 May 2019; Accepted: 6 February 2020;
Published: xx xx xxxx
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